Elanco Animal Health Inc (ELAN)

$14.30 +0.54 (3.92%)
Market Cap 6.83B
Revenue (ttm) 4.44B
Net Income (ttm) 338.00M
EPS (ttm) N/A
PE Ratio 14.37
Forward PE 16.18
Profit Margin 7.61%
Debt to Equity Ratio 0.69
Volume 6,267,400
Avg Vol 6,185,832
Day's Range N/A - N/A
Shares Out 496.65M
Stochastic %K 94%
Beta 1.67
Analysts Strong Sell
Price Target $15.05

Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Crede...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 877 352 6261
Address:
2500 Innovation Way, Greenfield, United States
JarvisFlow
JarvisFlow Jun. 26 at 12:00 PM
William Blair updates rating for Elanco Animal Health ( $ELAN ) to Outperform.
0 · Reply
DonCorleone77
DonCorleone77 Jun. 12 at 8:23 PM
$ELAN Elanco's Zenrelia granted positive opinion by EU veterinary product committee Elanco announced that Zenrelia - ilunocitinib - has been granted a positive opinion by the European Medicines Agency's Committee for Veterinary Medicinal Products, or CVMP, paving the way for the product's marketing authorization in the European Union in the next 60 days. The CVMP recommended granting the marketing authorization based on the quality, safety and efficacy demonstrated in the data submitted and the favorable benefit-risk balance. Elanco expects to launch the product shortly after receiving marketing authorization with supply in the marketplace before the end of Q3. Zenrelia is already available in Brazil, Canada, Japan and the U.S., and the company expects additional approvals in Australia and the U.K. in 2025.
0 · Reply
SaylorsPonz
SaylorsPonz Jun. 11 at 9:37 PM
is there a worse name than $ELAN ?
1 · Reply
macroaxis
macroaxis May. 30 at 3:45 AM
$ELAN - Elanco options price warning: put open interest is down to 3420.0 https://www.macroaxis.com/stock-options/ELAN/Elanco-Animal-Health?utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
MyChicago
MyChicago May. 29 at 4:50 PM
$ZOMDF $WOOF $ELAN $CHWY
0 · Reply
DonCorleone77
DonCorleone77 May. 28 at 11:34 AM
$ELAN Elanco backs FY25 adjusted EPS view 80c-86c, consensus 84c Backs FY25 revenue view $4.51B-$4.58B, consensus $4.53B. Backs FY25 adjusted EBITDA view $830M-$870M.
0 · Reply
DonCorleone77
DonCorleone77 May. 28 at 11:33 AM
$ELAN Elanco still sees Q2 adjusted EPS 17c-21c, consensus 20c Still sees Q2 revenue $1.18B-$1.2B, consensus $1.19B. Still sees Q2 adjusted EBITDA $200M-$220M.
0 · Reply
DonCorleone77
DonCorleone77 May. 28 at 11:31 AM
$ELAN Elanco appoints Robert VanHimbergen as CFO Elanco appointed Robert VanHimbergen as EVP and CFO, effective July 7. VanHimbergen succeeds Todd Young, who will remain with the company as an advisor through August 31, to facilitate a smooth transition. VanHimbergen currently serves as the SVP and CFO of Hillenbrand. Prior to joining Hillenbrand, he spent 15 years at Johnson Controls. He previously held roles within Johnson Controls, including CFO of the $9B automotive interiors business in Shanghai, China, and led the battery division in Asia. Prior to Johnson Controls, VanHimbergen spent nearly a decade at PricewaterhouseCoopers.
0 · Reply
OptionRunners
OptionRunners May. 23 at 4:49 PM
$ELAN Buyer of the June 20th $13 puts (ITM) 1,648 times for $0.76-$0.80
0 · Reply
Estimize
Estimize May. 13 at 10:00 AM
Wall St is expecting 0.22 EPS for $ELAN Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/elan?chart=historical&metric_name=eps&utm_co
0 · Reply
Latest News on ELAN
Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise

Jun 26, 2025, 2:38 PM EDT - 12 hours ago

Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise

Elanco Releases 2024 Impact Report and Introduces New Framework

Jun 26, 2025, 1:00 PM EDT - 13 hours ago

Elanco Releases 2024 Impact Report and Introduces New Framework

Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products (CVMP)

Jun 12, 2025, 4:17 PM EDT - 14 days ago

Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products (CVMP)

Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

Jun 5, 2025, 7:45 AM EDT - 21 days ago

Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer

May 28, 2025, 7:25 AM EDT - 4 weeks ago

Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer

Elanco to Participate in the Upcoming Investor Conferences

May 16, 2025, 8:00 AM EDT - 5 weeks ago

Elanco to Participate in the Upcoming Investor Conferences

Elanco: Deleveraging Takes Time

May 12, 2025, 4:26 AM EDT - 6 weeks ago

Elanco: Deleveraging Takes Time

Elanco Animal Health Incorporated (ELAN) Q1 2025 Earnings Call Transcript

May 7, 2025, 12:52 PM EDT - 7 weeks ago

Elanco Animal Health Incorporated (ELAN) Q1 2025 Earnings Call Transcript

Animal Health Elanco Chirps A Solid Quarter Tempered By Soft Q2 EPS Guide

May 7, 2025, 11:03 AM EDT - 7 weeks ago

Animal Health Elanco Chirps A Solid Quarter Tempered By Soft Q2 EPS Guide

Elanco Animal Health Reports First Quarter 2025 Results

May 7, 2025, 6:27 AM EDT - 7 weeks ago

Elanco Animal Health Reports First Quarter 2025 Results

Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Connect

May 6, 2025, 10:00 AM EDT - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Connect

Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal

May 5, 2025, 4:40 PM EDT - 7 weeks ago

Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal

BX

Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown

May 5, 2025, 6:27 AM EDT - 7 weeks ago

Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown

TARS

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Reach Out

May 4, 2025, 10:00 AM EDT - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Shareholders to Learn More About the Investigation

May 1, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Shareholders to Learn More About the Investigation

Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 29, 2025, 10:00 AM EDT - 2 months ago

Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Apr 24, 2025, 10:00 AM EDT - 2 months ago

Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Trade Tracker: Sarat Sethi buys Zoetis and sells Elanco

Apr 23, 2025, 1:16 PM EDT - 2 months ago

Trade Tracker: Sarat Sethi buys Zoetis and sells Elanco

ZTS

Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Connect

Apr 22, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Connect

Elanco's Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Annual National Parvo Awareness Day

Apr 22, 2025, 8:27 AM EDT - 2 months ago

Elanco's Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Annual National Parvo Awareness Day

Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Stockholders to Inquire about Securities Investigation

Apr 20, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Investors to Learn More About the Investigation

Apr 17, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Stockholders to Connect

Apr 15, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Stockholders to Connect

Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Apr 13, 2025, 10:00 AM EDT - 2 months ago

Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Stockholders to Learn More About the Investigation

Apr 10, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Stockholders to Learn More About the Investigation

Elanco Confirms Date and Conference Call for First Quarter 2025 Financial Results Announcement

Apr 10, 2025, 8:00 AM EDT - 2 months ago

Elanco Confirms Date and Conference Call for First Quarter 2025 Financial Results Announcement

Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Investors to Inquire about Securities Investigation

Apr 8, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Reach Out

Apr 6, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Shareholders to Inquire about Securities Investigation

Mar 30, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Shareholders to Inquire about Securities Investigation

Elanco Announces Changes to Board of Directors; Signs Research Agreement to Explore Novel Therapies for Chronic Kidney Disease and Life Extension in Pets

Mar 17, 2025, 4:17 PM EDT - 3 months ago

Elanco Announces Changes to Board of Directors; Signs Research Agreement to Explore Novel Therapies for Chronic Kidney Disease and Life Extension in Pets

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Stockholders to Reach Out

Mar 4, 2025, 10:00 AM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Stockholders to Reach Out

Elanco Animal's Outlook Lags Street Expectations But Analyst Sees Time For Elanco's Commercial Investment To Payoff

Feb 25, 2025, 1:38 PM EST - 4 months ago

Elanco Animal's Outlook Lags Street Expectations But Analyst Sees Time For Elanco's Commercial Investment To Payoff

Elanco Animal Health Incorporated (ELAN) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 10:59 AM EST - 4 months ago

Elanco Animal Health Incorporated (ELAN) Q4 2024 Earnings Call Transcript

Elanco Enters Agreement with Medgene to Commercialize Highly Pathogenic Avian Influenza Vaccine in Dairy Cattle

Feb 25, 2025, 7:05 AM EST - 4 months ago

Elanco Enters Agreement with Medgene to Commercialize Highly Pathogenic Avian Influenza Vaccine in Dairy Cattle

Elanco Animal Health Reports Fourth Quarter and Full Year 2024 Results

Feb 25, 2025, 7:05 AM EST - 4 months ago

Elanco Animal Health Reports Fourth Quarter and Full Year 2024 Results

Elanco to Participate in Upcoming Investor Conferences

Feb 21, 2025, 8:00 AM EST - 4 months ago

Elanco to Participate in Upcoming Investor Conferences

Elanco Launches Pet Protect™ From the Makers of Advantage®: Veterinarian-Formulated Supplements for Complete Pet Wellness

Feb 20, 2025, 8:27 AM EST - 4 months ago

Elanco Launches Pet Protect™ From the Makers of Advantage®: Veterinarian-Formulated Supplements for Complete Pet Wellness

Elanco Reinforces Commitment to Veterinary and Pet Owner Education

Feb 13, 2025, 4:29 PM EST - 4 months ago

Elanco Reinforces Commitment to Veterinary and Pet Owner Education

Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2024 Financial Results Announcement

Feb 4, 2025, 8:00 AM EST - 5 months ago

Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2024 Financial Results Announcement

Meet the Faces of Zen: Elanco's Zenrelia™ (ilunocitinib tablets) Helps Allergic Dogs Get Back to Normal

Jan 27, 2025, 8:06 AM EST - 5 months ago

Meet the Faces of Zen: Elanco's Zenrelia™ (ilunocitinib tablets) Helps Allergic Dogs Get Back to Normal

Elanco Animal Health: Building On Success

Jan 15, 2025, 6:42 AM EST - 5 months ago

Elanco Animal Health: Building On Success

Elanco to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 19, 2024, 11:07 AM EST - 6 months ago

Elanco to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

ELAN Deadline Today: Rosen Law Firm Urges Elanco Animal Health Incorporated (NYSE: ELAN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Dec 6, 2024, 11:51 AM EST - 7 months ago

ELAN Deadline Today: Rosen Law Firm Urges Elanco Animal Health Incorporated (NYSE: ELAN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

ELAN Deadline: ELAN Investors Have Opportunity to Lead Elanco Animal Health Incorporated Lawsuit

Dec 6, 2024, 12:20 AM EST - 7 months ago

ELAN Deadline: ELAN Investors Have Opportunity to Lead Elanco Animal Health Incorporated Lawsuit

DEADLINE APPROACHING: The Schall Law Firm Encourages Shareholder Contributions To A Fraud Case Against Elanco Animal Health Incorporated

Dec 5, 2024, 10:15 AM EST - 7 months ago

DEADLINE APPROACHING: The Schall Law Firm Encourages Shareholder Contributions To A Fraud Case Against Elanco Animal Health Incorporated

JarvisFlow
JarvisFlow Jun. 26 at 12:00 PM
William Blair updates rating for Elanco Animal Health ( $ELAN ) to Outperform.
0 · Reply
DonCorleone77
DonCorleone77 Jun. 12 at 8:23 PM
$ELAN Elanco's Zenrelia granted positive opinion by EU veterinary product committee Elanco announced that Zenrelia - ilunocitinib - has been granted a positive opinion by the European Medicines Agency's Committee for Veterinary Medicinal Products, or CVMP, paving the way for the product's marketing authorization in the European Union in the next 60 days. The CVMP recommended granting the marketing authorization based on the quality, safety and efficacy demonstrated in the data submitted and the favorable benefit-risk balance. Elanco expects to launch the product shortly after receiving marketing authorization with supply in the marketplace before the end of Q3. Zenrelia is already available in Brazil, Canada, Japan and the U.S., and the company expects additional approvals in Australia and the U.K. in 2025.
0 · Reply
SaylorsPonz
SaylorsPonz Jun. 11 at 9:37 PM
is there a worse name than $ELAN ?
1 · Reply
macroaxis
macroaxis May. 30 at 3:45 AM
$ELAN - Elanco options price warning: put open interest is down to 3420.0 https://www.macroaxis.com/stock-options/ELAN/Elanco-Animal-Health?utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
MyChicago
MyChicago May. 29 at 4:50 PM
$ZOMDF $WOOF $ELAN $CHWY
0 · Reply
DonCorleone77
DonCorleone77 May. 28 at 11:34 AM
$ELAN Elanco backs FY25 adjusted EPS view 80c-86c, consensus 84c Backs FY25 revenue view $4.51B-$4.58B, consensus $4.53B. Backs FY25 adjusted EBITDA view $830M-$870M.
0 · Reply
DonCorleone77
DonCorleone77 May. 28 at 11:33 AM
$ELAN Elanco still sees Q2 adjusted EPS 17c-21c, consensus 20c Still sees Q2 revenue $1.18B-$1.2B, consensus $1.19B. Still sees Q2 adjusted EBITDA $200M-$220M.
0 · Reply
DonCorleone77
DonCorleone77 May. 28 at 11:31 AM
$ELAN Elanco appoints Robert VanHimbergen as CFO Elanco appointed Robert VanHimbergen as EVP and CFO, effective July 7. VanHimbergen succeeds Todd Young, who will remain with the company as an advisor through August 31, to facilitate a smooth transition. VanHimbergen currently serves as the SVP and CFO of Hillenbrand. Prior to joining Hillenbrand, he spent 15 years at Johnson Controls. He previously held roles within Johnson Controls, including CFO of the $9B automotive interiors business in Shanghai, China, and led the battery division in Asia. Prior to Johnson Controls, VanHimbergen spent nearly a decade at PricewaterhouseCoopers.
0 · Reply
OptionRunners
OptionRunners May. 23 at 4:49 PM
$ELAN Buyer of the June 20th $13 puts (ITM) 1,648 times for $0.76-$0.80
0 · Reply
Estimize
Estimize May. 13 at 10:00 AM
Wall St is expecting 0.22 EPS for $ELAN Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/elan?chart=historical&metric_name=eps&utm_co
0 · Reply
Quantumup
Quantumup May. 12 at 3:54 PM
BofA Asks and Answers: on a, "Potential reset / reduction of China tariffs: Who stands to benefit the most? — Biggest beneficiaries: TMO [Buy-$545], AVTR , DHR [Buy-$230], RVTY [Buy-$116], $MTD, $ILMN [Underperform-$70]" $ELAN BofA said in its note:
0 · Reply
Armymike1981
Armymike1981 May. 10 at 2:38 PM
$ELAN this movement is only the beginning !!! Up until now Zoetis was selling products that were only in their arsenal … now with zenrelia, Quattro and gallaprant… their reign is over!! I would be shorting Zoetis from this point!
0 · Reply
JarvisFlow
JarvisFlow May. 8 at 1:50 PM
Stifel updates rating for Elanco Animal Health ( $ELAN ) to Buy, target set at 13 → 15.
0 · Reply
SwanStefan
SwanStefan May. 8 at 10:54 AM
$QVCGB $QRTEB $GOCO $HALO $ELAN
0 · Reply
LewisDaKat
LewisDaKat May. 7 at 6:55 PM
$ELAN News out Connection, Joy, Gizmo: Dr. Joya Griffin https://marketwirenews.com/news-releases/connection-joy-gizmo-dr-joya-griffin-5415388920579925.html $ELAN
0 · Reply
DimebagDarrell_
DimebagDarrell_ May. 7 at 6:23 PM
$ELAN We are OUT! Love trading this stock. We’ll be back when the time is right.
0 · Reply
lecorb
lecorb May. 7 at 12:45 PM
$ELAN https://seekingalpha.com/news/4443040-elanco-stock-spikes-q1-beat?mailingid=39751587&messageid=2900&serial=39751587.362&source=email_2900&utm_campaign=rta-stock-news&utm_content=link-3&utm_medium=email&utm_source=seeking_alpha&utm_term=39751587.362
0 · Reply
OpenOutcrier
OpenOutcrier May. 7 at 12:30 PM
$ELAN (+8.8% pre) Elanco (NYSE:ELAN) Beats Q1 Sales Targets, Full-Year Outlook Slightly Exceeds Expectations https://ooc.bz/l/63797
0 · Reply
RMAW
RMAW May. 7 at 12:29 PM
$ELAN BULLISH LOOONG TERM!!!!
0 · Reply
lecorb
lecorb May. 7 at 10:56 AM
$ELAN Elanco Non-GAAP EPS of $0.37 beats by $0.07, revenue of $1.19B beats by $20M
0 · Reply
DonCorleone77
DonCorleone77 May. 7 at 10:52 AM
$ELAN Elanco sees Q2 adjusted EPS 17c-21c, consensus 25c Sees Q2 revenue $1.18B-$1.2B, consensus $1.18B. Sees Q2 adjusted EBITDA $200M-$220M.
0 · Reply
DonCorleone77
DonCorleone77 May. 7 at 10:52 AM
$ELAN Elanco backs FY25 adjusted EPS view 80c-86c, consensus 83c Raises FY25 revenue view to $4.51B-$4.58B from $4.45B-$4.51B, consensus $4.5B. Backs FY25 adjusted EBITDA view $830M-$870M. "We are raising our 2025 full-year revenue guidance and maintaining our adjusted EBITDA and adjusted EPS ranges, reflecting our strong first quarter execution, recent momentum and more favorable foreign exchange rates, balanced by expected tariff impact and a cautious approach in an uncertain macroeconomic environment," said Todd Young, Executive Vice President and CFO of Elanco Animal Health. "On tariffs, we have taken several intervention actions, positioning us well to cover potential impacts with or without the pharmaceutical exemption. We are also accelerating our debt paydown to approximately half a billion dollars this year, now expecting to end 2025 with a net leverage ratio of 3.9x to 4.3x."
0 · Reply